Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (symbol: CGEN) is a cutting-edge drug discovery company specializing in developing therapeutic proteins and monoclonal antibodies to meet critical needs in immunology and oncology. By leveraging a sophisticated infrastructure of proprietary scientific insights, predictive platforms, algorithms, and machine learning systems, Compugen excels in in silico (computer-based) prediction and selection of promising product candidates for its pipeline program.
Compugen's business model is robust and diversified, encompassing partnerships and collaborations for the further development and commercialization of its product candidates. These collaborations typically offer milestone payments and royalties on product sales, providing Compugen with multiple revenue streams. The company's U.S. subsidiary, based in South San Francisco, focuses on developing monoclonal antibodies.
At the core of Compugen's operations is its clinical-stage therapeutic discovery and development efforts, primarily in cancer immunotherapy. Its comprehensive immuno-oncology pipeline includes four clinical-stage programs, each targeting immune checkpoints discovered through computational methods. Notable programs include COM701, COM902, and bapotulimab. These programs are designed to tackle various mechanisms of immune resistance, with a particular focus on myeloid targets.
Recent achievements highlight Compugen's forward momentum. The company announced it would release its fourth quarter and full-year 2023 financial results on March 5, 2024. Compugen's President and CEO, Anat Cohen-Dayag, emphasized the company's strong financial footing, collaboration successes, and the anticipated catalytic milestones in 2024.
Key partnerships enhance Compugen’s clinical progress. For instance, the company has a license agreement with Gilead Sciences for COM503, a first-in-class antibody program against IL-18 binding protein. This agreement includes a $60 million upfront payment and a $30 million milestone payment upon IND clearance.
Another significant partnership is with AstraZeneca, which is advancing a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 into Phase 3 development. This program, rilvegostomig, targets biliary tract cancer and nonsquamous non-small cell lung cancer. These collaborations underscore the extensive potential and validation of Compugen's computational discovery platform.
Compugen's financial health is robust, with a reported cash balance of $101.3 million as of March 31, 2024, ensuring operational funding into 2027. The company has demonstrated prudent financial management, achieving net revenues and reducing operational losses over time.
Headquartered in Israel, with additional offices in San Francisco, Compugen is listed on both Nasdaq and the Tel Aviv Stock Exchange, making it a prominent player in the biotech sector. For investors and stakeholders, Compugen represents a beacon of innovation and potential in cancer immunotherapy.
Compugen Ltd. (CGEN) announced the publication of preclinical data on COM902, a novel anti-TIGIT therapeutic antibody, in Cancer Immunology, Immunotherapy. Key findings show that COM902 enhances anti-tumor immune responses by blocking TIGIT, which is expressed in various solid tumors. It demonstrates no T cell depletion activity, potentially preserving immune function. The ongoing Phase 1 trial for COM902 is expected to report initial results in Q4 2021, with further studies combining it with other therapies planned for H2 2021.
Compugen Ltd. (Nasdaq: CGEN) announced the publication of a review article in Cancer Discovery discussing the DNAM-1 axis's role in cancer immunotherapy. Co-authored by Drew Pardoll, M.D., Ph.D., the article covers key molecules such as DNAM-1, TIGIT, and PVRIG, highlighting their therapeutic relevance. It also discusses the potential of combining DNAM-1 axis blockers with PD-1/L1 agents, aiming to expand treatment options for new patient populations. Compugen is conducting Phase 1 studies on its anti-PVRIG antibody, COM701, and TIGIT-targeting antibody, COM902, focusing on the clinical evaluation of these approaches.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. The presentation will be available via live webcast on Compugen's website, with an option for replay afterward. Compugen focuses on developing therapeutics for cancer immunotherapy, featuring its lead candidate COM701, which is in a Phase 1 clinical study. The company also has another candidate, COM902, targeting TIGIT, currently in a Phase 1 trial. Compugen operates from Israel and has a presence in South San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) reported its financial results for Q4 and full year 2020. Revenues for Q4 were $2.0 million, primarily from a milestone payment from AstraZeneca. R&D expenses rose to $8.1 million in Q4 and $22.8 million for the year, driven by clinical studies and manufacturing activities. The net loss for Q4 was $8.6 million, with total cash reserves at approximately $124.4 million as of year-end. Compugen is focusing on expanding clinical programs for its immunotherapy candidates, showcasing encouraging data for COM701 in refractory cancer patients.
Compugen Ltd. (CGEN) announced updated data from its Phase 1 study of COM701, an investigational antibody targeting PVRIG, reporting a 66.7% disease control rate when combined with Opdivo®. Key results included a confirmed complete response in a previously unresponsive patient and ongoing durable responses over a year in several patients. The company plans to expand the study to include patients with ovarian, breast, endometrial, and colorectal cancers. Compugen aims to evaluate dual and triple blockade regimens, enhancing the potential of its innovative immunotherapy approach.
Compugen Ltd. (CGEN) announced an expanded clinical collaboration with Bristol Myers Squibb to evaluate COM701, a first-in-class anti-PVRIG antibody, in a Phase 1b cohort study. This study will combine COM701 with Opdivo® (nivolumab) and is set to begin in Q2 2021. Initial results from dose escalation show preliminary antitumor activity. The study will focus on patients with ovarian, breast, endometrial, and colorectal cancers, aiming to provide insights on treatment efficacy through monotherapy, dual, and triple combination therapies.
Compugen Ltd. (Nasdaq: CGEN) will release its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. markets open. A conference call will follow at 8:30 AM ET for management to discuss the results and provide updates. Compugen specializes in cancer immunotherapy and predictive target discovery, with key products COM701 and COM902 currently in Phase 1 clinical studies. The company is headquartered in Israel and has offices in South San Francisco, CA, with shares traded on Nasdaq and the Tel Aviv Stock Exchange.
Compugen Ltd. (Nasdaq: CGEN) announces participation in several virtual investor conferences. Key events include the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 AM ET, the Jefferies Virtual Healthcare Conference on November 18, 2020, at 5:35 AM ET, and the Evercore ISI HealthCONx Conference on December 1, 2020, at 9:40 AM ET. Live webcasts will be available on the Compugen website, with replays accessible post-event. The company is focused on cancer immunotherapy, with its lead product COM701 in Phase 1 clinical studies.
Compugen Ltd. (NASDAQ: CGEN) reported its Q3 2020 financial results, revealing a net loss of $7.8 million, or $0.09 per share, an increase from $6.5 million, or $0.10 per share, in Q3 2019. R&D expenses rose to $5.5 million from $4.3 million due to ongoing clinical studies. A noteworthy milestone was the initiation of a Phase 1/2 study for the anti-PVRIG antibody, COM701, in combination with Bristol Myers Squibb's Opdivo® and an investigational TIGIT antibody. Compugen's cash reserves reached approximately $133 million, significantly up from $44 million at year-end 2019.
Compugen Ltd. (CGEN) has received a new patent from the China National Intellectual Property Administration for COM902, an immuno-oncology therapeutic antibody targeting TIGIT. This patent extends the protection for COM902 beyond existing patents in the U.S. and Europe and covers its composition for cancer treatment. The patent is valid until at least August 2037. COM902 is currently in a Phase 1 clinical trial, showing potential to enhance T cell responses against tumors when combined with PD-1 inhibitors. This development reflects Compugen's commitment to expanding its immuno-oncology pipeline.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen Ltd's primary business focus?
What makes Compugen unique in the biotech industry?
Who are Compugen's key partners?
What are some of Compugen's notable products?
What recent financial milestones has Compugen achieved?
Where is Compugen Ltd headquartered?
On which stock exchanges are Compugen's shares listed?
What are some of Compugen's recent achievements?
What is the significance of Compugen’s computational discovery platform?
What is Compugen's approach to advancing its pipeline?
